Diisopropyl 8-bromo-2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine was used as a starting material for the synthesis of the 8-C-substituted 2,6-diamino-9-[2-(phosphonomethoxy)ethyl]purine (PMEDAP) analogues. A systematic screening of diverse cross-coupling reactions was carried out. Stille, Suzuki–Miyaura, Negishi, and Sonogashira cross-couplings, as well as Pd-catalysed reactions with trialkylaluminiums, were employed for the introduction of various alkyl, alkenyl, alkynyl, aryl, and hetaryl substituents to the C-8 position of the 2,6-diaminopurine moiety. In contrast to the potent parent compound PMEDAP, which exhibits potent antiretroviral and antitumor activity, none of the sixteen newly synthesized 8-C-substituted analogues of PMEDAP showed any specific antiviral activity.
以 8-溴-2,6-二氨基-9-[2-(磷酰甲氧基)乙基]嘌呤二异丙基为起始原料,合成了 8-C 取代的 2,6-二氨基-9-[2-(磷酰甲氧基)乙基]嘌呤 (PMEDAP) 类似物。对各种交叉偶联反应进行了系统筛选。在 2,6-二氨基嘌呤分子的 C-8 位置引入各种烷基、烯基、炔基、芳基和己基取代基时,采用了 Stille、Suzuki-Miyaura、Negishi 和 Sonogashira 交叉耦合反应,以及与三烷基铝的钯催化反应。母体化合物 PMEDAP 具有很强的抗逆转录病毒和抗肿瘤活性,与之形成鲜明对比的是,新合成的 16 种 8-C 取代的 PMEDAP 类似物均未显示出任何特异性抗病毒活性。